Key Insights

Highlights

Treatment Research

9 treatments under study, led by Ui059

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Not Yet Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07727629Phase 1Not Yet RecruitingPrimary

Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers

NCT02584751Phase 1UnknownPrimary

GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals

Showing all 2 trials

Research Network

Common Treatments

  • Ui0591
  • Exhaled Nitric Oxide1
  • Omeprazole1
  • Uic2022011
  • Bernsteins Acid Clearance Test1

Active Sponsors

  • James J. Peters Veterans Affairs Medical Center1
  • Korea United Pharm. Inc.1

Top Investigators

Activity Timeline